Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 98.95 INR
Change Today -0.40 / -0.40%
Volume 13.9K
CBTL On Other Exchanges
Symbol
Exchange
Mumbai
As of 6:10 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

camson bio technologies ltd (CBTL) Snapshot

Open
99.90
Previous Close
99.35
Day High
102.00
Day Low
98.30
52 Week High
11/7/14 - 164.00
52 Week Low
06/3/15 - 81.00
Market Cap
3.0B
Average Volume 10 Days
25.6K
EPS TTM
0.67
Shares Outstanding
30.0M
EX-Date
09/15/14
P/E TM
147.7x
Dividend
--
Dividend Yield
1.01%
Current Stock Chart for CAMSON BIO TECHNOLOGIES LTD (CBTL)

Related News

No related news articles were found.

camson bio technologies ltd (CBTL) Related Businessweek News

No Related Businessweek News Found

camson bio technologies ltd (CBTL) Details

Camson Bio Technologies Limited operates as an agriculture biotechnology company in India. The company offers biocides, natural fertilizers, and bio fertilizers and stimulants. It also provides hybrid vegetables seeds, including lady’s finger, bottle gourd, bitter gourd, ridge gourd, sweet corn, baby corn, tomato, brinjal, chilli, and sponge gourd; and hybrid fruit seeds comprising watermelon and musk melon. The company markets its products through distributors and dealers. Camson Bio Technologies Limited was founded in 1993 and is headquartered in Bengaluru, India.

camson bio technologies ltd (CBTL) Top Compensated Officers

Managing Director, Executive Director and Cha...
Total Annual Compensation: 3.8M
Compensation as of Fiscal Year 2014.

camson bio technologies ltd (CBTL) Key Developments

Camson Bio Technologies Limited Reports Audited Standalone Earnings Results for the Fourth Quarter and Year Ended March 31, 2015

Camson Bio Technologies Limited reported audited standalone earnings results for the fourth quarter and year ended March 31, 2015. For the quarter, net sales/income from operation was INR 374.969 million against INR 391.098 million a year ago. Loss from operation before other income, finance cost and exceptional item was INR 65.577 million against profit from operation before other income, finance cost and exceptional item of INR 78.535 million a year ago. Loss from ordinary activities before tax was INR 22.859 million against profit from ordinary activities before tax of INR 65.820 million a year ago. Net loss was INR 31.447 million or INR 1.10 per diluted share against net profit of INR 81.586 million or INR 2.72 per diluted share a year ago. For the year, net sales/income from operation was INR 1,693.815 million against INR 1,456.278 million a year ago. Profit from operation before other income, finance cost and exceptional item was INR 27.830 million against INR 195.690 million a year ago. Profit from ordinary activities before tax was INR 50.479 million against INR 126.702 million a year ago. Net profit was INR 30.823 million or INR 1.07 per diluted share against INR 132.712 million or INR 4.72 per diluted share a year ago.

Camson Bio Technologies Limited, Board Meeting, May 19, 2015

Camson Bio Technologies Limited, Board Meeting, May 19, 2015. Agenda: To consider audited standalone and consolidated earnings results for the fourth quarter and year ended March 31, 2015.

Camson Bio Technologies Limited Reports Unaudited Consolidated and Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Camson Bio Technologies Limited reported unaudited consolidated and standalone earnings results for the third quarter and nine months ended December 31, 2014. For the quarter on consolidated basis, the company reported total income from operations of INR 635.115 million compared to INR 542.039 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 40.162 million compared to INR 35.052 million a year ago. Profit from ordinary activities before tax was INR 33.471 million compared to INR 26.540 million a year ago. Net profit for the period was INR 14.480 million or INR 0.58 per diluted share before and after extraordinary items compared to INR 24.340 million or INR 0.79 per diluted share before and after extraordinary items a year ago. For the nine months, on consolidated basis, the company total income from operations of INR 1,568.523 million compared to INR 1,513.991 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 92.309 million compared to INR 117.451 million a year ago. Profit from ordinary activities before tax was INR 67.364 million compared to INR 60.177 million a year ago. Net profit for the period was INR 56.296 million or INR 2.00 per diluted share before and after extraordinary items compared to net profit of INR 51.332 million or INR 1.66 per diluted share before and after extraordinary items a year ago. For the quarter, on standalone basis, the company reported total income from operations of INR 545.851 million compared to INR 438.836 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 42.041 million compared to INR 34.906 million a year ago. Profit from ordinary activities before tax was INR 37.971 million compared to INR 26.394 million a year ago. Net profit for the period was INR 19.553 million or INR 0.65 per diluted share before and after extraordinary items compared to net profit of INR 24.238 million or INR 0.79 per diluted share and after extraordinary items a year ago. For the nine months, on standalone basis, the company reported total income from operations of INR 1,318.846 million compared to INR 1,065.180 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 93.407 million compared to INR 117.155 million a year ago. Profit from ordinary activities before tax was INR 73.338 million compared to INR 59.882 million a year ago. Net profit for the period was INR 62.270 million or INR 2.08 per diluted share before and after extraordinary items compared to net profit of INR 51.126 million or INR 1.66 per diluted share before and after extraordinary items a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBTL:IN 98.95 INR -0.40

CBTL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanta Ltd 472.30 INR 0.00
JK Agri Genetics Ltd 500.00 INR 0.00
Kaveri Seed Co Ltd 727.95 INR 0.00
Monsanto India Ltd 3,016 INR 0.00
View Industry Companies
 

Industry Analysis

CBTL

Industry Average

Valuation CBTL Industry Range
Price/Earnings 100.0x
Price/Sales 1.4x
Price/Book 1.1x
Price/Cash Flow 18.4x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAMSON BIO TECHNOLOGIES LTD, please visit www.camsonbiotechnologies.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.